The following post comes from Austin Shaffer, a 2L at Scalia Law and a Research Assistant at CPIP. By Austin Shaffer This past fall, the Department of Justice (DOJ) and […]
[Archived Post] IP Scholars Question the Legality and Wisdom of Joint AG Proposal to Seize Remdesivir Patents
The following post comes from Colin Kreutzer, a 2E at Scalia Law and a Research Assistant at CPIP. By Colin Kreutzer While the vaccines are starting to roll out in […]
[Archived Post] Professor Joanna Shepherd Explains Pharmaceutical Product Hopping in New CPIP Policy Brief
CPIP has published a new policy brief by Joanna M. Shepherd, Vice Dean and Thomas Simmons Professor of Law at Emory University School of Law. The brief, entitled The Legal […]
[Archived Post] New Paper Looks at “Ill-Advised Legislative Proposals” to Address Pharmaceutical “Evergreening”
The following post comes from Yumi Oda, an LLM Candidate at Scalia Law and a Research Assistant at CPIP. By Yumi Oda Many believe that drug prices in the U.S. […]
[Archived Post] Recent Developments in the Life Sciences: The Continuing Assault on Innovation by Antitrust Plaintiffs in Lantus
By Erika Lietzan In February, the U.S. Court of Appeals for the First Circuit held, in a direct purchaser antitrust action, that an innovative pharmaceutical company marketing an injectable drug […]
[Archived Post] CPIP Scholars Join Comments to FTC on How Antitrust Overreach is Threatening Healthcare Innovation
On December 21, 2018, CPIP Senior Scholars Adam Mossoff and Kristen Osenga joined former Federal Circuit Chief Judge Randall Rader and SIU Law’s Mark Schultz in comments submitted to the […]
[Archived Post] Recognizing the Limits of Government Procurement in the Pharmaceutical Industries
While recent headlines claim that rising drug prices can be easily addressed through government intervention, the procedures involved with government use of patented technologies are complex and often misunderstood. In […]
[Archived Post] A Cure Worse Than the Disease? Proposed Changes to European Patent Law are Threatening Pharmaceutical Innovation
Innovation is all around us. We love and appreciate the latest video games, software apps, and smartphones. We await the integration of self-driving cars and other forms of artificial intelligence. […]
[Archived Post] Proposal for Drug Price Controls is Legally Unprecedented and Threatens Medical Innovation
By Adam Mossoff, Sean O’Connor, & Evan Moore* The price of the miracle drugs everyone uses today is cause for concern among people today. The President has commented on it. […]
[Archived Post] New CPIP Policy Brief: An Unwise Move to Discriminate Against Pharmaceutical Patents
CPIP has published a new policy brief entitled An Unwise Move to Discriminate Against Pharmaceutical Patents: Responding to the UN’s Guidelines for Pharmaceutical Patent Examination. The brief, written by CPIP […]